Suggested remit: To appraise the clinical and cost effectiveness of selumetinib within its marketing authorisation for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over.
Status Proposed
Process STA 2018
ID number 1590

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
01 November 2019 (10:00) Scoping workshop (London)
19 September 2019 - 17 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance